Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Passage Bio (NASDAQ: PASG) said management will present and hold investor meetings at two upcoming conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference on Feb 26, 2026 (virtual; presentation 8:40 a.m. ET) and TD Cowen 46th Annual Health Care Conference on Mar 4, 2026 (Boston; presentation 1:50 p.m. ET).
A live webcast will be available on the company's Investors & Media page and a replay will be accessible for 30 days after each event.
Passage Bio (NASDAQ: PASG) reported Q3 2025 results and program updates for PBFT02 targeting frontotemporal dementia (FTD). The company is actively enrolling Dose 2 patients in Cohort 3 (5–10 FTD‑GRN) and Cohort 4 (3–5 FTD‑C9orf72) of the upliFT‑D study and amended the protocol to add short‑course prophylactic anticoagulation and broaden early‑stage enrollment.
Passage aligned with the FDA on an analytical comparability plan for a 200‑L suspension‑based manufacturing process that produced a batch estimated to yield >1,000 doses at >90% purity and >70% full capsids. The company plans to seek FDA feedback on a registrational FTD‑GRN trial in 1H 2026 and expects to report updated interim safety and biomarker data from Dose 2 in 1H 2026. Cash, cash equivalents and marketable securities were $52.8M as of Sept 30, 2025, with runway into 1Q 2027. Q3 net loss was $7.7M ($2.44 per share, post 1‑for‑20 reverse split).
Passage Bio (NASDAQ: PASG) announced that Will Chou, M.D., president and CEO, will participate in a fireside chat at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston.
A live webcast will be available on the company’s Investors & News website at investors.passagebio.com, and a replay will be available for 90 days following the event.
Passage Bio (NASDAQ: PASG) announced that Will Chou, M.D., president and chief executive officer, will participate in a panel at the Chardan 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 3:30 p.m. ET in New York City.
A live webcast will be available on the company’s Investors & News webpage at investors.passagebio.com, and a replay will be accessible for 90 days following the event.
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company specializing in neurodegenerative diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.
CEO Will Chou, M.D., will deliver a company overview presentation and the management team will engage in one-on-one investor meetings. The presentation will be available via video webcast to conference attendees starting September 5, 2025, at 7:00 a.m. ET, with a 30-day replay period accessible through the company's investor relations website.
Passage Bio (NASDAQ: PASG) has reported Q2 2025 financial results and clinical progress for its FTD-GRN program. The company completed dosing of Cohort 2 in the upliFT-D study, with PBFT02 showing promising results including durable elevation in CSF progranulin levels and improved disease progression biomarkers compared to natural history.
Financial highlights include a cash position of $57.6 million, reduced R&D expenses to $5.8M from $10.4M YoY, and a narrowed net loss of $9.4M compared to $16.0M YoY. The company's cash runway extends into Q1 2027.
Key upcoming milestones include seeking regulatory feedback on manufacturing process in 2H 2025 and trial design in 1H 2026, along with reporting updated interim data from Dose 2 in 1H 2026.
Passage Bio (NASDAQ:PASG), a clinical-stage genetic medicines company, has announced a 1-for-20 reverse stock split effective July 14, 2025. The split will reduce outstanding common shares from approximately 62.4 million to 3.1 million.
The reverse split aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The move was approved by stockholders at the 2025 annual meeting on May 28. Stockholders will not need to take action, as positions will be automatically adjusted, with fractional shares rounded up to the nearest whole share.
The company's trading symbol "PASG" will remain unchanged, though a new CUSIP number (702712 209) will be assigned.Passage Bio (NASDAQ: PASG) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its PBFT02 program for FTD-GRN patients. Interim data showed promising results, with Dose 1 PBFT02 increasing CSF progranulin levels from below 3 ng/mL to 13-27 ng/mL at six months and 22-34 ng/mL at 12 months.
The company has enrolled its first patient for Dose 2 PBFT02, which is 50% lower than Dose 1. Financial results show cash position of $76.8 million as of December 31, 2024, with runway extended into Q1 2027. Net loss for 2024 was $64.8 million ($1.07 per share), improved from $102.1 million in 2023. R&D expenses decreased to $40.2 million from $61.4 million, while G&A expenses reduced to $25.0 million from $41.6 million year-over-year.